Erica Farrand, MD
Assistant Professor
Medicine
School of Medicine

Dr. Farrand's scholarship focuses on defining, assessing and improving the health care quality, safety and outcomes for individuals with interstitial lung disease. She collaborates closely with colleagues in ILD, health services research, implementation science and informatics to support a multidisciplinary research program.

• Digital outcome measures in pulmonary clinical trials.
  Current opinion in pulmonary medicine 2023 Farrand E, Swigris JJ
• Machine-Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease.
  American journal of respiratory and critical care medicine 2023 Farrand E, Gologorskaya O, Mills H, Radhakrishnan L, Collard HR, Butte AJ
• Extracting patient-level data from the electronic health record: Expanding opportunities for health system research.
  PloS one 2023 Farrand E, Collard HR, Guarnieri M, Minowada G, Block L, Lee M, Iribarren C
• Addressing health disparities through implementation science-a need to integrate an equity lens from the outset.
  Implementation science : IS 2022 Kerkhoff AD, Farrand E, Marquez C, Cattamanchi A, Handley MA
• Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease.
  Chest 2021 Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR,…
• Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination.
  Thorax 2021 DeDent AM, Farrand E
• Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems.
  Clinics in chest medicine 2021 Farrand E, Limper AH
• Strategies for forming effective women's groups.
  The clinical teacher 2020 Santhosh L, Harleman E, Venado A, Farrand E, E Gilbreth M, Keenan BP, Thompson VV, Shah RJ
• Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients.
  Chest 2020 Farrand E, Iribarren C, Vittinghoff E, Levine-Hall T, Ley B, Minowada G, Collard HR
• Is corticosteroid use truly not associated with improved outcomes in AE-IPF? - Reply.
  Respirology (Carlton, Vic.) 2020 Farrand E, Collard HR
• Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF.
  Respirology (Carlton, Vic.) 2019 Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR
• Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data.
  American journal of respiratory and critical care medicine 2019 Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez FJ, Collard HR
• The Hospitalized Patient with Interstitial Lung Disease: A Hospitalist Primer.
  Journal of hospital medicine 2017 Farrand E, Shah R, Collard H
• Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.
  Digestive diseases and sciences 2012 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL
• Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus.
  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012 Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS
• Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
  Transplantation 2011 Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, Guarrera JV, Brown RS